<DOCUMENT>
<TYPE>EX-2
<SEQUENCE>3
<FILENAME>feb2020038kexhibit2.txt
<DESCRIPTION>STOCK PURCHASE AND SEVERANCE AGREEMENT
<TEXT>
EX-2

             STOCK PURCHASE AND SEVERANCE AGREEMENT

    THIS  AGREEMENT dated as of the 4th day of February, 2003  by
and  among Fermtech AS, a joint stock company incorporated in the
kingdom  of  Norway ("Fermtech"),  Igene Biotechnology,  Inc.,  a
Maryland  corporation, U.S.A. ("Igene"), Stein Ulve ("Ulve")  and
Per Benjaminsen ("Benjaminsen").

    WHEREAS,  Igene own 10,000 shares of common stock (being  all
of  the issued and outstanding shares and herein referred  to  as
"the  Shares") of ProBio Nutraceuticals AS, referred to  also  as
Igene  Norway  AS ("ProBio"), a joint stock company  incorporated
under  the  laws of the Kingdom of Norway (Business  Registration
Number NO 982 197 902 MVA);

    WHEREAS, Fermtech is desirous of buying from Igene and  Igene
is desirous of selling to Fermtech all of the Shares;

    WHEREAS,  Ulve is the Chief Executive Officer  of  Igene  and
Benjaminsen  is the Chief Operating Officer of Igene pursuant  to
Agreements dated October 9, 2001.

    WHEREAS, Igene, Ulve and Benjaminsen are desirous of  finding
an  amicable severance solution for Ulve from the position as the
CEO  of  Igene and Benjaminsen from the position of  Director  of
Marketing  and  Sales  of  ProBio  and  the  termination  of  the
aforementioned Agreements;

    NOW,   THEREFORE,  WITNESSETH,  in  consideration  of   these
premises  and  the mutual covenants, agreements,  representations
and  warranties contained herein, the parties hereto hereby agree
as follows:

    1.    Fermtech  shall  purchase  the  Shares  from  Igene  in
exchange  for  7,000,000  shares  of  Igene  currently  owned  by
Fermtech.

    2.    2,000,000 of the shares of Igene shall be delivered  to
Mr. Cecil Martin at McGuire Woods to be held in escrow.  Provided
Benjaminsen  remains  employed by Igene  (or  any  subsidiary  or
affiliate) through 2003, 1,000,000 shares shall be released  from
escrow  and  returned to Fermtech.  Provided Benjaminsen  remains
employed by Igene (or any subsidiary or affiliate) through  2004,
the  remaining 1,000,000 shares shall be released from escrow and
returned  to Fermtech.  In the event Benjaminsen does not  fulfil
the  employment  with  Igene as aforesaid, the  shares  shall  be
delivered to Igene.

    3.    The existing  Agreement of Benjaminsen dated October 9,
2001  shall  be considered to be void.  Additionally, Benjaminsen
shall  resigns/cancels  any employment relationship  with  ProBio
effective  December 31, 2002, to work full time  for  Igene  from
same  date, under the terms of a new agreement  to be established
by   Benjaminsen   and   Igene.    Under   this   agreement   the
title/position,  allowances  and  other  compensation  terms   of
Benjaminsen  might  be  changed by Igene,  but  Benjaminsen  will
retain  the current base salary of US$ 100,000 annually  and  the
ability   to   earn  options   outlined  in  the   aforementioned
agreement.

    4.    The outstanding receivables and payables as of November
1st   between Igene and ProBio shall be cancelled. For ProBio the
receivable  is $585,364,84.00 (NOK 4,033,163.76 at NOK/USD  6,89)
due by Igene to ProBio. For Igene the receivable is $4,250.01 (or
NOK 29,282).  All of  these plus any incurred to date,  with  the
exception  of  the following, will be forgiven.  An  invoice  for
December  2002 of $20,410.00 (NOK 148,918.86, Benjaminsen salary,
Ulve  salary, and audit cost from KPMG related to translation  of
financial  statements for year ended 2001 etc), less  salary  for
Ulve  $9,585., less tax and personal insurance $1,252, net $9,573
will be assumed by Igene and paid.

    5.    The  existing Assignment Agreement of Stein Ulve  dated
October 9,2001 shall be considered to be void, except for options
as mentioned below.  Ulve will resign as CEO of Igene, as well as
resigning  his  position  on the Board  of  Directors,  effective
December  31st  2002  and is to receive no additional  salary  or
benefits   from  Igene. The parties acknowledged  that  Ulve  has
earned  options  for  3,333,333 shares of  Igene  @  $0.08  which
options shall be valid and executable until January 22, 2004.

    6.    Representations  and   Warranties  of   Igene.    Igene
represents and warrants to Fermtech as follows:

    a.    It   possesses   all  requisite  power  and   authority
necessary  to  carry  out the transactions contemplated  by  this
Agreement.

    b.    It  owns  beneficially and of record and has  good  and
marketable title to the Shares, free and clear of all liens.

    c.    To the best of its knowledge, the books and records  of
ProBio  accurately reflect the assets and liabilities  of  ProBio
and  it  has  or  knows  of no claims or obligations,  actual  or
alleged  which  are  not reflected in the books  and  records  of
ProBio.

    7.    Representations  and Warranties of Fermtech.   Fermtech
represents and warrants to Igene as follows:

    a.    It   possesses   all  requisite  power  and   authority
necessary  to  carry  out the transactions contemplated  by  this
Agreement.

    b.    It  owns  beneficially and of record and has  good  and
marketable title to the 7,000,000 shares of Igene, free and clear
of all liens.

    8.    Akvaforsk.     Igene acknowledges that Akvaforsk claims
that  it  is due approximately $40,000 from ProBio and/or  Igene.
The  parties hereto agree that any sums due to Akvaforsk  related
to  the  Igene Modelling Project, are the obligation  of   Igene.
Igene  shall,  at  its  expense,  defend  this  claim  and  shall
indemnify  ProBio against the claim and any expenses incurred  by
ProBio in defending same.

    9.    Web  domains.  Igene and ProBio will split the  current
Igene  web pages; all feed related material to be used  by  Igene
and  all nutraceutical related material to be used by ProBio. The
current  web  site  itself and the domain www.probio.no  will  be
retained by ProBio, and Igene will retain www.igene.com.

    10.    Names,  Trademarks,  Patents.    ProBio has no  names,
trademarks or patents, except the Trademark "Rubia". It is agreed
that  Igene  retain rights to all names, trademarks, and  patents
related to Igene's feed ingredient business, including the use of
the trademark AstaXin(R), and the name "Igene Norway",  developed
before  or  during the period when both companies were  combined.
ProBio  will retain the right to its only registered  trade  name
"Rubia" for Nutraceutical use.

    11.    Fees.  All fees and expenses incurred by any  party in
connection with this Agreement will be borne by such party.

    12.    Miscellaneous.   All  relevant   material,   archives,
sensitive  information  related   to  AstaXin(R),  production  of
AstaXin(R), trade secrets, etc  will be returned safely to Igene,
or destroyed in agreement with instructions from Igene.

    IN   WITNESS  WHEREOF,  the parties hereto have  causes  this
Agreement to be duly executed as of the day and year first  above
written.





ATTEST/WITNESS           IGENE BIOTECHNOLOGY, INC.


                         BY: /S/  MICHAEL KIMELMAN
____________________         __________________________ (SEAL)
                                  MICHAEL KIMELMAN
                                  Chairman of the Board


                          FERMTECH AS


                         BY: /S/  PER BENJAMINSEN
____________________         __________________________ (SEAL)
                                  PER BENJAMINSEN


                             /S/  STEIN ULVE
____________________         __________________________ (SEAL)
                                  STEIN ULVE


                             /S/  PER BENJAMINSEN
____________________         __________________________ (SEAL)
                                  PER BENJAMINSEN

</TEXT>
</DOCUMENT>
